Vanda Pharmaceuticals (VNDA) stock price, revenue, and financials

Vanda Pharmaceuticals market cap is $513.7 m, and annual revenue was $227.19 m in FY 2019

$513.7 M

VNDA Mkt cap, 22-Sept-2020

$62.2 M

Vanda Pharmaceuticals Revenue Q2, 2020
Vanda Pharmaceuticals Net income (Q2, 2020)8.7 M
Vanda Pharmaceuticals EBIT (Q2, 2020)9.2 M
Vanda Pharmaceuticals Cash, 30-Jun-202095.3 M
Vanda Pharmaceuticals EV430.1 M

Vanda Pharmaceuticals Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

7.4m8.0m8.1m8.4m8.3m8.1m8.3m8.7m9.1m10.9m14.8m22.2m27.6m28.3m33.3m36.0m38.5m37.4m42.1m41.3m43.6m47.4m49.1m47.7m59.1m59.5m58.0m62.2m

Cost of goods sold

198.0k703.0k5.0m5.8m6.5m6.0m6.5m7.0m4.0m4.5m4.5m4.6m5.2m5.1m5.1m6.4m6.8m

Gross profit

10.7m14.1m17.1m21.8m21.8m27.3m29.5m31.5m33.4m37.5m36.8m39.0m42.1m44.1m42.6m52.7m52.7m

Gross profit Margin, %

98%95%77%79%77%82%82%82%89%89%89%90%89%90%89%89%89%

R&D expense

6.0m8.2m12.2m12.5m10.2m8.0m6.0m8.0m7.3m3.5m3.7m4.5m5.9m10.0m7.5m6.7m7.3m10.6m7.6m10.2m9.4m9.9m11.4m13.3m11.0m11.3m15.5m12.9m

General and administrative expense

2.6m2.7m3.9m3.6m3.1m4.0m5.1m5.7m27.9m28.1m11.3m18.8m18.4m18.5m29.3m24.7m21.9m30.3m31.4m31.1m26.8m28.0m26.0m31.0m31.5m30.2m37.0m33.9m

Operating expense total

8.6m10.9m16.1m16.1m13.3m11.9m11.1m13.7m35.2m32.3m15.5m27.4m27.3m31.4m39.8m34.3m32.1m41.3m39.5m41.7m36.6m38.2m37.8m44.7m42.8m41.9m52.5m46.8m

Depreciation and amortization

377.0k565.0k617.0k536.0k4.1m2.9m2.9m2.9m2.9m2.9m454.0k432.0k432.0k352.0k398.0k397.0k379.0k369.0k

EBIT

(1.5m)(3.3m)(8.3m)(8.1m)(5.4m)(4.2m)(3.1m)(5.4m)(26.6m)(21.6m)(1.4m)(10.3m)(5.5m)(9.5m)(12.5m)(4.8m)(653.0k)(7.9m)(1.9m)(4.9m)2.4m3.9m6.2m(2.1m)9.9m10.8m(125.0k)9.2m

EBIT margin, %

(20%)(41%)(102%)(97%)(65%)(52%)(37%)(62%)(291%)(199%)(10%)(46%)(20%)(34%)(38%)(13%)(2%)(21%)(5%)(12%)6%8%13%(4%)17%18%0%15%

Interest income

121.0k106.0k

Pre tax profit

(1.4m)(3.2m)(8.0m)(8.0m)(5.3m)(4.2m)(3.1m)(5.4m)(26.5m)(21.6m)(7.6m)(1.5m)(4.5m)3.1m4.7m7.3m(602.0k)11.5m12.3m1.2m11.1m

Income tax expense

(51.0k)(113.0k)19.0k7.0k23.0k(2.0k)90.0k92.0k10.0k18.0k(88.1m)755.0k2.4m

Net Income

(1.3m)(3.1m)(8.0m)(8.0m)(5.3m)(4.2m)(3.1m)(5.4m)(26.5m)(21.6m)(1.4m)(10.2m)(5.4m)(9.5m)(12.4m)(4.6m)(430.0k)(7.6m)(1.5m)(4.5m)3.1m4.6m7.2m(612.0k)11.5m100.4m486.0k8.7m

Vanda Pharmaceuticals Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

87.9m88.8m64.8m60.9m50.8m40.4m33.6m61.0m45.1m

Accounts Receivable

1.6m1.2m2.0m3.7m16.3m20.3m17.6m28.8m26.4m

Prepaid Expenses

3.9m2.7m3.1m5.7m8.0m12.0m14.5m

Inventories

57.0k5.2m1.3m779.0k840.0k994.0k1.1m

Current Assets

153.5m126.0m135.6m141.7m166.5m174.2m169.9m299.1m354.1m

PP&E

964.0k2.3m2.2m2.4m4.6m5.0m5.3m4.4m3.9m

Total Assets

182.6m135.4m143.3m171.7m213.1m210.4m205.4m332.1m483.7m

Accounts Payable

996.0k287.0k661.0k835.0k15.8m16.2m20.3m21.6m27.6m

Short-term debt

5.5m

Current Liabilities

31.6m32.3m32.9m7.8m51.3m50.3m70.4m53.0m59.5m

Long-term debt

12.5m

Total Debt

5.5m12.5m

Total Liabilities

149.1m125.5m99.2m10.9m80.0m79.0m74.0m56.7m72.8m

Common Stock

28.0k28.0k33.0k41.0k43.0k45.0k52.0k54.0k

Preferred Stock

Additional Paid-in Capital

296.9m301.0m355.4m448.7m460.8m477.1m492.8m611.6m631.3m

Retained Earnings

(263.4m)(291.1m)(311.4m)(288.0m)(327.8m)(345.9m)(361.4m)(336.2m)(220.7m)

Total Equity

33.5m9.9m44.1m160.8m133.0m131.3m131.4m275.4m410.9m

Debt to Equity Ratio

0.6 x

Debt to Assets Ratio

0 x

Financial Leverage

5.5 x13.7 x3.2 x1.1 x1.6 x1.6 x1.6 x1.2 x1.2 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

50.4m60.3m108.1m94.4m104.5m109.9m103.6m142.2m43.3m17.0m15.3m32.8m48.3m46.8m38.7m23.2m32.8m20.1m14.2m22.6m155.3m60.9m60.8m34.4m46.5m39.2m65.0m95.3m

Accounts Receivable

752.0k1.2m1.5m1.7m1.5m1.5m1.6m2.0m1.7m2.4m3.7m20.1m15.8m15.8m16.7m14.0m15.9m17.8m21.0m18.2m23.3m24.9m25.3m26.3m23.9m26.8m29.3m24.6m

Prepaid Expenses

2.5m3.3m3.3m2.7m2.4m3.1m4.2m3.8m2.5m7.0m10.0m6.5m9.4m11.0m12.2m15.7m10.7m9.3m11.8m12.1m11.2m10.7m14.4m17.8m15.0m

Inventories

165.0k161.0k21.0k28.0k192.0k1.1m1.3m5.2m5.0m3.8m938.0k927.0k865.0k816.0k742.0k921.0k1.0m1.2m887.0k1.1m1.1m1.0m1.3m1.4m

Current Assets

191.5m164.7m161.3m150.0m139.9m116.1m108.4m147.1m105.5m71.2m64.8m162.2m174.4m173.9m162.4m160.4m170.4m168.6m174.6m169.7m282.4m269.1m278.8m306.5m315.8m280.0m360.7m380.9m

PP&E

963.0k851.0k2.5m2.5m2.4m2.3m2.2m2.1m2.2m2.3m2.2m3.1m3.9m4.2m4.4m4.2m4.7m5.5m5.7m5.4m5.1m4.8m4.6m4.3m4.2m4.2m3.9m3.7m

Total Assets

203.4m195.7m172.6m160.8m149.8m125.1m117.0m155.1m121.0m86.2m79.2m213.6m223.7m220.5m206.7m202.0m208.4m204.7m210.7m205.7m317.3m302.9m311.9m351.2m372.5m474.4m488.5m506.6m

Accounts Payable

1.3m1.3m780.0k1.7m1.1m1.1m1.2m369.0k953.0k248.0k547.0k1.5m1.6m45.9m22.7m17.9m17.6m18.0m19.1m18.9m17.2m18.6m19.0m27.4m29.3m27.0m26.0m28.4m

Short-term debt

5.8m6.2m

Current Liabilities

32.9m33.6m32.7m34.4m34.6m32.0m31.9m31.9m45.4m38.3m38.8m31.8m45.2m45.9m55.0m51.8m50.7m73.0m75.4m71.5m72.0m46.9m46.2m59.3m62.6m60.0m59.2m61.6m

Long-term debt

13.3m13.0m12.8m12.1m11.7m

Total Debt

5.8m6.2m13.3m13.0m12.8m12.1m11.7m

Total Liabilities

163.9m158.1m145.7m140.8m134.5m118.7m111.9m105.1m100.0m85.3m78.1m61.2m73.9m74.6m83.7m80.4m79.3m76.6m79.3m75.2m76.2m51.7m50.5m72.8m75.8m73.5m72.1m75.0m

Common Stock

28.0k28.0k28.0k28.0k28.0k28.0k28.0k33.0k34.0k34.0k34.0k42.0k42.0k43.0k43.0k43.0k44.0k45.0k45.0k45.0k52.0k52.0k52.0k53.0k53.0k53.0k54.0k55.0k

Preferred Stock

Additional Paid-in Capital

294.3m295.5m298.3m299.5m300.0m301.7m303.4m353.7m355.6m357.1m358.7m450.6m453.3m458.9m463.1m466.3m474.2m481.6m486.4m489.9m599.5m604.9m607.9m615.0m621.6m625.5m635.7m642.4m

Retained Earnings

(254.8m)(257.9m)(271.4m)(279.4m)(284.7m)(295.3m)(298.4m)(303.7m)(334.7m)(356.3m)(357.7m)(298.2m)(303.6m)(313.1m)(340.2m)(344.8m)(345.3m)(353.5m)(355.0m)(359.6m)(358.4m)(353.7m)(346.6m)(336.8m)(325.3m)(224.9m)(220.2m)(211.5m)

Total Equity

39.5m37.7m26.9m20.1m15.4m6.5m5.0m50.0m21.0m885.0k1.1m152.5m149.7m145.9m123.0m121.6m129.2m128.1m131.4m130.5m241.1m251.3m261.4m278.4m296.7m400.9m416.4m431.6m

Debt to Equity Ratio

0.9 x1.2 x0 x0 x

Debt to Assets Ratio

0 x0.1 x0 x0 x

Financial Leverage

5.1 x5.2 x6.4 x8 x9.8 x19.3 x23.3 x3.1 x5.8 x97.4 x74.5 x1.4 x1.5 x1.5 x1.7 x1.7 x1.6 x1.6 x1.6 x1.6 x1.3 x1.2 x1.2 x1.3 x1.3 x1.2 x1.2 x1.2 x

Vanda Pharmaceuticals Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(1.2m)(4.3m)(8.0m)(16.0m)(21.3m)(4.2m)(7.3m)(12.6m)(26.5m)(48.1m)(49.5m)(10.2m)(15.6m)(25.1m)(12.4m)(17.0m)(17.4m)(7.6m)(9.2m)(13.7m)3.1m7.7m14.8m(612.0k)10.9m111.3m486.0k9.2m

Depreciation and Amortization

138.0k284.0k331.0k424.0k528.0k107.0k212.0k1.4m690.0k1.4m2.1m4.3m7.3m10.4m3.2m6.3m9.5m704.0k1.4m2.2m701.0k1.5m1.1m332.0k672.0k1.0m351.0k694.0k

Accounts Receivable

(241.0k)(705.0k)83.0k(82.0k)83.0k(294.0k)(473.0k)(788.0k)340.0k(345.0k)(1.7m)(16.5m)(12.2m)(12.1m)(348.0k)2.3m52.0k2.5m(756.0k)2.1m(5.7m)(7.3m)(7.7m)2.4m4.9m1.9m(2.9m)1.7m

Inventories

(165.0k)(161.0k)(192.0k)(1.1m)(1.3m)(45.0k)208.0k1.4m130.0k(109.0k)63.0k(83.0k)(7.0k)(896.0k)63.0k(71.0k)215.0k(44.0k)(191.0k)(896.0k)76.0k10.0k

Accounts Payable

689.0k685.0k(216.0k)693.0k94.0k826.0k880.0k82.0k292.0k(413.0k)(114.0k)654.0k796.0k38.4m6.9m2.2m1.7m1.4m2.6m2.6m(2.7m)(1.6m)(3.2m)3.5m5.2m3.2m(1.8m)883.0k

Cash From Operating Activities

(8.9m)(16.1m)(8.7m)(20.9m)(31.1m)(9.1m)(17.2m)(27.4m)(23.9m)(60.6m)(68.2m)5.6m17.7m12.8m(4.9m)(8.2m)(6.9m)(5.4m)(7.6m)(5.4m)1.6m6.0m14.7m9.6m30.2m36.2m(907.0k)23.1m

Purchases of PP&E

(164.0k)(198.0k)(1.8m)(2.0m)(2.0m)(23.0k)(72.0k)(79.0k)(135.0k)(378.0k)(431.0k)(783.0k)(939.0k)(1.8m)(111.0k)(710.0k)(478.0k)(1.1m)(1.5m)(135.0k)(210.0k)(346.0k)(393.0k)(657.0k)(951.0k)(373.0k)(583.0k)

Cash From Investing Activities

16.7m33.8m28.9m27.4m47.7m30.5m31.4m31.4m389.0k10.8m16.5m(33.6m)(30.7m)(31.0m)(7.2m)(20.5m)(18.2m)(17.2m)(23.0m)(17.6m)16.3m(85.0m)(93.9m)(36.5m)(48.2m)(62.1m)20.3m23.0m

Cash From Financing Activities

5.0k(193.0k)601.0k49.4m2.0m2.0m2.2m(79.0k)513.0k4.1m24.0k1.0m7.0m2.2m4.4m5.2m103.7m106.2m106.3m179.0k3.6m4.1m479.0k4.1m

Net Change in Cash

7.8m17.8m20.2m6.5m16.6m21.2m14.9m53.4m(21.5m)(47.8m)(49.5m)(28.1m)(12.6m)(14.1m)(12.1m)(27.6m)(18.1m)(20.3m)(26.2m)(17.8m)121.7m27.3m27.2m(26.6m)(14.5m)(21.8m)19.9m50.2m

Vanda Pharmaceuticals Ratios

USDQ2, 2011

Financial Leverage

5.1 x

Vanda Pharmaceuticals Employee Rating

2.518 votes
Culture & Values
2.2
Work/Life Balance
2.9
Senior Management
1.9
Salary & Benefits
2.9
Career Opportunities
2.1
Source